2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4-((3-oxo-2,2,4- triazol-5-yl)methyl)rnorpholine (1): A potent, orally active, morpholine-based human neurokinin-1 receptor antagonist

Journal of Medicinal Chemistry

Volumn 39, Issue 9, 1996, Pages 1760-1762

  Hale, Jeffrey J ^a   Mills, Sander G ^a   MacCoss, Malcolm ^a   Shah, Shrenik K ^a   Qi, Hongbo ^a   Mathre, David J ^a   Cascieri, Margaret A ^a   Sadowski, Sharon ^a   Strader, Catherine D ^a   MacIntyre, D Euan ^a   Metzger, Joseph M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 4 (3 OXO 1,2,4 TRIAZOL 5 YLMETHYL) 3 PHENYLMORPHOLINE; 2 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL]OXY] 4 [(3 OXO 1,2,4 TRIAZOL 5 YL)METHYL] 3 PHENYLMORPHOLINE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; CALCIUM CHANNEL; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; CHO CELLS; CRICETINAE; HUMANS; MORPHOLINES; RECEPTORS, NEUROKININ-1;

EID: 0029878786     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950654w     Document Type: Article

References (34)

1. (a) Longmore, J.; Swain, C. J.; Hill, R. G. Neurokinin Receptors. Drug News Perspect, 1995, 8, 5-23.
2. (b) Moussaoui, S. M.; Montier, F.; Carruette, A.; Blanchard, J. C.; Laduron, P. M.; Garret, C. A. Non-Peptide NK1-Receptor Antagonist, RP 67580, Inhibits Neurogenic Inflammation Postsynaptically. Br. J. Pharmacol. 1993, 109, 259-264.
3. (c) Vaught, J. L. Substance P Antagonists and Analgesia: A Review of the Hypothesis. Life Sci. 1988, 43, 1419-1431.
4. Weisman, M. H.; Hagaman, C.; Yaksh, T. L.; Lotz, M. Preliminary Findings on the Role of Neuropeptide Suppression by Topical Agents in the Management of Rheumatoid Arthritis. Semin. Arthritis Rheum. 1994, 23, 18-24.
5. Joos, G. F.; Germonpre, P. R.; Kips, J. C.; Peleman, R. A.; Pauwels, R. A. Sensory Neuropeptides and the Human Lower Airways: Present State and Future Directions. Eur. Respir. J. 1994, 7, 1161-1171.
6. Julia, V.; Morteau, O.; Bueno, L. Involvement of Neurokinin 1 and 2 Receptors in Viscerosensitive Response to Rectal Distension in Rats. Gastroenterology 1994, 107, 94-102.
7. Regoli, D.; Boudon, A.; Fauchere, J.-L. Receptors and Antagonists for Substance P and Related Peptides. Pharm. Rev. 1994, 46, 551-599.
8. Snider, R. M.; Constantine, J. W.; Lowe, J. A.; Longo, K. P.; Lebel, W. S.; Woody, H. A.; Drozda, S. E.; Desai, M. C.; Vinick, F. J.; Spencer, R. W.; Hess, H. J. A Potent Non-Peptide Antagonist of the Substance P (NK1) Receptor. Science 1991, 251, 435-437.
9. Desai, M. C. Recent Advances in the Discovery and Characterization of Substance P Antagonists. Exp. Opin. Ther. Patents 1994, 4, 315-321 and references therein.
10. (a) Constantine, J. W.; Lebel, W S.; Woody, H. A.; Benoit, P. A.; Wolfgang, E. A.; Knight, D. R. Cardiovascular Effects of CP-96,345, A Non-Peptide Blocker of Tachykinin NK-1 Receptors. Eur. J. Pharmacol. 1994, 252, 275-282.
11. 2+ Channels. Eur. J. Pharmacol. 1994, 267, 113-115.
12. 2+ Channels. Eur. J. Pharmacol. 1992, 215, 351-352.
13. (d) Nagahisa, A.; Asai, R.; Kanai, Y.; Murase, A.; Tsuchiya-Nakgaki, M.; Nakagaki, T.; Shieh, T.-C.; Taniguchi, K. Non-Specific Activity of (±)-CP-96,345 in Models of Pain and Inflammation. Br. J. Pharmacol. 1992, 107, 273-275.
14. (a) McLean, S.; Snider, R. M.; Desai, M. C.; Rosen, T.; Bryce, D. K.; Longo, K. P.; Schmidt, A. W.; Heym, J. CP-99,994, A Nonpeptide Antagonist of the Tachykinin NK1 Receptor. Regul. Pept. 1993, 46, 329-331.
15. (b) McLean, S.; Ganong, A.; Seymour, P. A.; Snider, R. M.; Desai, M. C.; Rosen, T.; Bryce, D. K.; Longo, K. P.; Reynolds, L. S.; Robinson, G.; Schmidt, A. W.; Siok, C.; Heym, J. Pharmacology of CP-99,994; a Nonpeptide Antagonist of the Tachykinin Neurokinin-1 Receptor. J. Pharmacol. Exp. Ther. 1993, 267, 472-479.
16. Harrison, T.; Williams, B. J.; Swain, C. J.; Ball, R. G. Piperidine-Ether Based hNK1 Antagonists 1: Determination of the Relative and Absolute Stereochemical Requirements. Bioorg. Med. Chem. Lett. 1994, 4, 2545-2550.
17. (a) Harrison, T.; Owens, A. P.; Williams, B. J.; Swain, C. J.; Baker, R.; Hutson, P. H.; Sadowski, S.; Cascieri, M. A. Piperidine-Ether Based h-NK1 Antagonists 2: Investigation of the Effect of N-Substitution. Bioorg. Med. Chem. Lett. 1995, 5, 209-212.
18. (b) Ladduwahetty, T.; Baker, R.; Cascieri, M. A.; Chambers, M. S.; Haworth, K.; Keown, L.; MacIntyre, D. E.; Metzger, J. M.; Owen, S.; Rycroft, W.; Sadowski, S.; Seward, E. M.; Shepeard, S.; Swain, C. J.; Tattersall, F. D.; Williamson, D.; Hargreaves, R. J. N-Heteroaryl-2-Phenyl-3-Benzyloxypiperidines: A Novel Class of Potent, Orally Active Human NK-1 Antagonists. Manuscript submitted to J. Med. Chem.
19. Rekka, A.; Kourounakis, P. Synthesis, Physicochemical Properties and Biological Studies of Some Substituted 2-Alkoxy-4-Methyl-Morpholines. Eur. J. Med. Chem. 1989, 24, 179-185.
20. 1-Benzylamines.) Helv. Chim. Acta 1966, 49, 2481-2489.
21. Kashima, C.; Harada, K. Synthesis and Reaction of Optically Active Morpholinones. J. Chem. Soc., Perkin Trans. I 1988, 1521.
22. Czernecki, S.; Georgoulis, C.; Provelenghiou, C. Nouvelle Methode de Benzylation D'Hydroxyles Glucidiques Encombres. (Novel Method for the Benzyl Protection of Carbohydrate Hydroxyl Groups.) Tetrahedron Lett. 1976, 3535-3536.
23. Schmidt, R. R. Recent Developments in the Synthesis of Glycoconjugates. Pure Appl. Chem. 1989, 61, 1257-1270.
24. Yanagisawa, I.; Hirata, Y.; Ishii, Y. Histamine H2 Receptor Antagonists. 1. Synthesis of N-Cyano and N-Carbamoyl Amidine Derivatives and Their Biological Activities. J. Med. Chem. 1984, 27, 849-857.
25. The stereochemical purity was determined by supercritical fluid chromatography (SFC) using a novel two-column (achiral and chiral column in series) approach. For details, see the Supporting Information. For a review of chiral SFC, see: Petersson, P.; Markides, K E. J. Chromatogr. A 1994, 666, 381-394.
26. Cascieri, M. A.; Ber, E.; Fong, T. M.; Sadowski, S.; Bansal, A.; Swain, S.; Seward, E.; Frances, B.; Burns, D.; Strader, C. D. Characterization of the Binding of a Potent, Selective Radioiodinated Antagonist to the Human Neurokinin-1 Receptor. Mol. Pharmacol. 1992, 42, 458-465.
27. 125I]neurokinin A as the radioligand.
28. 3H]-Desmethoxyverapamil Labels Multiple Calcium Channel Modulator Receptors in Brain and Skeletal Muscle Membranes: Differentiation by Temperature and Dihydropyridines. J. Pharmacol. Exp. Ther. 1986, 237, 731-738.
29. (a) Williams, B. J.; Teall, M.; McKenna, J.; Harrison, T.; Swain, C. J.; Cascieri, M. A.; Sadowski, S.; Strader, C.; Baker, R. Acyclic NK-1 Antagonists: 2-Benzhydryl-2-Aminoethyl Ethers. Bioorg. Med. Chem. Lett. 1994, 4, 1903-1908.
30. (b) Mills, S. G.; MacCoss, M.; Cascieri, M. A.; Sadowski, S.; Patel, S.; Chapman, K. L.; Hutson, P. H. 1,2,4-Triacylpiperidine Substance P Antagonists: Separation of the Affinities for the NK-1 Receptor and the L-Type Calcium Channel. Bioorg. Med. Chem. Lett. 1995, 5, 599-604.
31. The United States Pharmacopeia (USP 23/NF 18), 1995, p 2053; United States Pharmacopeial Conventions, Inc., Rockville, MD.
32. The limits of detection of either standard compound by HPLC was determined to be ∼2%.
33. MacLeod, A. M.; Merchant, K. J.; Brookfield, F.; Kelleher, F.; Stevenson, G.; Owens, A. P.; Swain, C. J.; Cascieri, M. A.; Sadowski, S.; Ber, E.; Strader, C. D.; MacIntyre, D. E.; Metzger, J. M.; Ball, R. G.; Baker, R. Identification of L-Tryptophan Derivatives with Potent and Selective Antagonist Activity at the NK-1 Receptor. J. Med. Chem. 1994, 37, 1269.
34. Ward, et al. have noted that CP 99,994 is rapidly metabolized in dog hepatic microsomes and have suggested that first-pass metabolism is largely responsible for the low systemic plasma levels of this compound that are observed after oral dosing; see: Ward, P.; Armour, D. R.; Bays, D. E.; Evans, B.; Giblin, G. M. P.; Heron, N.; Hubbard, T.; Liang, K.; Middlemiss, D.; Mordaunt, J.; Naylor, A.; Pegg, N. A.; Vinader, V.; Watson, S. P.; Bountra, C.; Evans, D. C. Discovery of an Orally Bioavailable NK-1 Receptor Antagonist, (2S,3S)-2-Methoxy-5-tetrazol-l-ylbenzyl)-(2-phenylpiperidin-3-yl)amine (GR203040), with Potent Antiemetic Activity. J. Med. Chem 1995, 38, 4985.